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Medical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK and
3Department of Biological Sciences (Biomedical Science), The Allam Building, University of Hull, Cottingham Road, Hull HU6 7RX, UK
Background: Endo180 (CD280; MRC2; uPARAP)-dependent collagen remodelling is dysregulated in primary tumours and
bone metastasis. Here, we confirm the release and diagnostic accuracy of soluble Endo180 for diagnosing metastasis in breast
cancer (BCa).
Methods: Endo180 was quantified in BCa cell conditioned medium and plasma from BCa patients stratified according to disease
status and bisphosphonate treatment (n¼ 88). All P-values are from two-sided tests.
Results: Endo180 is released by ectodomain shedding from the surface of MCF-7 and MDA-MB-231 BCa cell lines. Plasma
Endo180 was significantly higher in recurrent/metastatic (1.71±0.87; n¼ 59) vs early/localised (0.92±0.37; n¼ 29) BCa (Po0.0001).
True/false-positive rates for metastasis classification were: 85%/50% for the reference standard, CA 15-3 antigen (28Uml 1);
p97%/X36% for Endo180; and p97%/X32% for CA 15-3 antigenþEndo180. Bisphosphonate treatment was associated
with reduced Endo180 levels in BCa patients with bone metastasis (P¼ 0.011; n¼ 42). True/false-positive rates in bisphosphonate-
naive patients (n¼ 57) were: 68%/45% for CA 15-3 antigen; p95%/X20% for Endo180; and p92%/X21% for CA 15-3 antigenþ
Endo180.
Conclusion: Endo180 is a potential marker modulated by bisphosphonates in metastatic BCa.
Breast cancer (BCa) is the most frequent malignancy in women in
the economically developed world (Ferlay et al, 2010). Despite
introduction of screening and advances in adjuvant therapy,
approximately one-third of early BCa patients will go on to develop
metastatic disease involving visceral organs and/or bone (Peto et al,
2012). In the majority of European centres, metastatic BCa is
monitored using the serum marker CA 15-3 antigen (Duffy et al,
2010), an epitope in the highly glycosylated transmembrane
protein mucin-1 (MUC-1) that is shed from the tumour cell
surface (Thathiah et al, 2003; Thathiah and Carson, 2004). Latest
recommendations for tumour markers in locally recurrent or
metastatic BCa published by the American Association of Clinical
Oncology in November 2007 (Harris et al, 2007) and the European
Society for Medical Oncology in June 2011 (Cardoso et al, 2011)
conclude that CA 15-3 antigen is useful as a marker together with,
but not as a replacement for, diagnostic imaging and routine
clinical assessment. Identification of markers that are more
sensitive, either alone or in combination with CA 15-3 antigen,
may help to improve this current diagnostic limitation for
metastatic BCa.
Endo180 (CD280; MRC2; urokinase plasminogen activator-
associated protein; uPARAP) is a 180-kDa type 1 transmembrane
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receptor that interacts with extracellular and intracellular collagens
(Wienke et al, 2003). Endo180 expression is correlated with
tumour grade, disease progression and poor prognosis in BCa
(Wienke et al, 2007), head and neck cancer (Sulek et al, 2007),
prostate cancer (Kogianni et al, 2009) and glioblastoma multiforme
(Huijbers et al, 2010). Endo180-dependent collagen remodelling
has mechanistic roles in the promotion of BCa progression (Curino
et al, 2005; Wienke et al, 2007) and metastatic bone lesion
pathology (Caley et al, 2011). In this study, we report that Endo180
ectodomain is released from BCa cells and measurement of soluble
Endo180 in plasma, alone or in combination with CA 15-3 antigen,
provides an accurate method for the classification of metastatic
disease. The results also indicate that Endo180 levels are modulated
following treatment with bisphosphonates.
PATIENTS AND METHODS
Preparation of conditioned medium and cell lysates. MCF-7-
Endo180 and MDA-MB-231 cells were cultured as previously
described (Sturge et al, 2003, 2006; Wienke et al, 2007). Protein
was precipitated from conditioned medium and cell lysates
prepared as described in Supplementary Materials and methods.
Immunoblot analysis. Conditioned medium pellets and corre-
sponding cell lysates were resolved using sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS–PAGE). Immunoblot
analysis was carried out using A5/158 or 39.10 mouse anti-human
Endo180 monoclonal antibodies (1 mgml 1) or CAT-2 rabbit anti-
mouse Endo180 polyclonal antibody (1.5 mgml 1) (Sturge et al,
2003, 2006, 2007; Wienke et al, 2007; Kogianni et al, 2009; Huijbers
et al, 2010; Caley et al, 2011) as described in Supplementary
Materials and methods.
Patients. Ethical approval for the study was obtained from
Imperial College Healthcare NHS Trust Tissue Bank Committee
(REC reference 07/MRE09/54). The study population was
restricted to a consecutive series of 92 patients with histologically
confirmed BCa who attended breast oncology clinics at Imperial
College Healthcare NHS Trust between 4 March 2011 and 29
August 2011 and was designed following the guidelines of
Standards for Reporting of Diagnostic accuracy studies (STARD)
(Bossuyt et al, 2003). Three patients were excluded from the study
due to incorrect completion of consent forms and one patient who
originally agreed to enter the study withdrew consent (Figure 1).
Treatment followed the standard of care that patients normally
receive at Imperial College Healthcare NHS Trust. Early BCa was
defined as a localised tumour previously treated with definitive
surgery, systemic therapy and adjuvant radiotherapy (as clinically
indicated) or receiving on-going (neo)-adjuvant systemic therapy.
All early BCa patients had a staging investigation that was negative
with no evidence of recurrent disease at outpatient review when
blood samples were collected. Metastatic disease sites were
determined from the most recent radiological evaluation. The
definition of visceral metastasis was radiological evidence of
recurrent disease involving the pleura, peritoneum or lymph nodes
(paratracheal, axillary, mediastinal, supraclavicular, infraclavicular)
or lesions in visceral organs (liver, lung, spleen). The definition of
bone metastasis was the detection of osseous lesions by bone
scintigraphy, computed tomography and/or magnetic resonance
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Figure 1. Details of patients included in the study. Number of patients recruited and excluded is shown together with those for whom index and
reference standard tests were performed. Numbers of patients with recurrent/locoregional disease, visceral metastasis, bone metastasis alone or
bone metastasis with visceral metastasis in lung, liver or more than one visceral site are indicated. Numbers of patients who were bisphosphonate
naive, had previously received, or were currently receiving, bisphosphonates are shown.
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imaging. Exclusion criteria were inadequate haematological and/or
biochemical parameters.
Plasma preparation and analysis. Plasma samples were collected
and Endo180 and CA 15-3 antigen levels were analysed as
described in Supplementary Materials and methods.
Statistical analysis. The Statistical Advisory Service (Imperial
College London) used SPSS software to predict that 17 patients
would be necessary for each patient group to detect low-to-
moderate correlation between variables (a¼ 5% probability, type 1
error significance level; 95% power; 50% confidence interval (CI);
40% standard deviation). Pearson’s correlation coefficient (r) was
calculated to determine assumed linearity. Kolmogorov–Smirnov
goodness of fit was used to test likelihood of a normal distribution
at 95% confidence. John Tukey criteria defined outliers as values
that were 1.5 times above the third quartile (Q3) or below the first
quartile (Q1). Non-parametric tests were used to calculate the
probability (P) of a significant difference (95% CI). Mann–Whitney
U-test was used for comparison between two groups. Kruskal–
Wallis one-way analysis of variance was used for comparison
between more than two groups. Where statistical differences were
found, Bonferonni multiple comparisons adjustment was applied
to confirm pairwise differences. For Bonferonni correction, the
overall type I error constraint was set to 0.05 and the level of
statistical significance was set to 0.05/n, where n is the number of
tests. P-valueso0.05/n were considered statistically significant. All
tests were two-sided. The test used for each analysis is cited in the
text and figure legends.
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Figure 2. Endo180 is cell membrane-associated or released in soluble form in monolayers of human BCa cell lines cultured under serum-free
conditions. (A) The domain structure of cell membrane-associated Endo180. The cysteine-rich domain (CRD), fibronectin type II domain (FNII) and
C-type lectin-like domains (CTLDs), of which there are eight (1–8); and binding sites of the known ligands for FNII (native collagen) and CTLD-2
(glycosylated collagen and sugar moieties); are shown. Three anti-Endo180 antibodies and their respective epitopes are depicted: mouse anti-
human Endo180 monoclonal antibody 39.10 is mapped to bind CTLD-4 (unpublished); mouse anti-human Endo180 monoclonal antibody A5/158
is mapped to bind CTLD-2 (Sturge et al, 2003); and rabbit anti-mouse CAT-2 monoclonal antibody was raised against the conserved 42 amino-acid
intracellular domain of mouse Endo180 and has equal affinity for the detection of the receptor in human cell lysates (Sturge et al, 2007; Caley et al,
2011). The domain structure of soluble Endo180 ectodomain following its juxtamembrane cleavage and predicted detection by 39.10 and A5/158
antibodies, but not CAT-2 antibody, is also shown. (B) MDA-MB-231 cells and (C) MCF-7 cells that overexpress Endo180 (MCF-7-Endo180) were
cultured in DMEM without fetal bovine serum for 0 (time zero), 6, 12, 24 and 48h at which time whole-cell lysates and corresponding conditioned
medium were collected. Samples were resolved on 8% w/v SDS polyacrylamide gels, transferred to polyvinylidene fluoride membranes and
immunoblot analysis was performed using the three anti-Endo180 monoclonal antibodies: 39.10 (1mgml 1), A5/158 (1mgml1) and CAT-2
(1.5mgml1); and a-tubulin monoclonal antibody (1/1000 dilution) and horse radish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG
(1/4000 dilution). Representative immunoblots from 10 experimental repeats are presented with corresponding graphs showing relative Endo180
levels calculated by the densitometric analysis of 39.10, A5/158 and CAT-2 immunoreactive bands. Relative Endo180 levels in conditioned media
(black bars) were calculated by normalisation against relative Endo180 levels at time zero (relative Endo180 level¼1.0) for all subsequent time
points (6, 12, 18 and 24h). Relative Endo180 levels in cell lysates (white bars) were adjusted against the level of a-tubulin and normalised against
the relative Endo180 levels at time zero (relative Endo180 level¼1.0) for all subsequent time points (6, 12, 18 and 24h). The markers of molecular
weight in kilodaltons (kDa) are indicated using black arrowheads for each immunoblot.
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RESULTS
Release of soluble Endo180. Viable disease markers are released
into the circulation in appreciable and easily detectable amounts
(Diamandis, 2010). Antibodies that bind epitopes in the ectodo-
main (A5/158 and 39.10) (Sturge et al, 2003) or intracellular
domain (CAT-2) (Sturge et al, 2007) of Endo180 (Figure 2A) were
used to immunoblot whole-cell lysates and corresponding condi-
tioned media from MDA-MB-231 and MCF-7-Endo180 cells, in
which the receptor enhances their pro-tumorigenic and metastatic
behaviour (Sturge et al, 2003, 2006; Wienke et al, 2003, 2007).
Endo180 detection by all three antibodies in MDA-MB-231
(Figure 2B) and MCF-7-Endo180 (Figure 2C) whole-cell lysates;
and by A5/158 and 39.10, but not CAT-2, in corresponding
conditioned media confirmed that Endo180 ectodomain is released
in a soluble form from BCa cells. Soluble Endo180 levels were
increased in MDA-MB-231 and MCF-7-Endo180 cell conditioned
media by 9.5-fold (after 12 h) and 42-fold (after 24 and 48 h)
culture in serum-free medium (Figure 2B and C).
Detection of soluble Endo180 in plasma. Immunodetection of
Endo180 by 39.10 antibody in human tissue and cell lysates has
been well characterised (Wienke et al, 2007; Kogianni et al, 2009;
Huijbers et al, 2010; Caley et al, 2011) and was adapted here as a
research assay in accordance with recommendations for initial
biomarker discovery where no commercial test exists (Pepe et al,
2008). A single and easily quantifiable 180 kDa immunoreactive
band could be detected by 39.10 antibody in plasma resolved using
SDS–PAGE (Supplementary Figure 1).
Elevated Endo180 in metastatic BCa. Endo180 levels in plasma
collected from 88 BCa patients (Figure 1) did not correlate with
their clincopathological characteristics or current treatment
(Supplementary Data; Supplementary Tables 1–3). The median
time from diagnosis of patients with early BCa (n¼ 29) was
5 months (range¼ 0–180 months; Q1: 3 months; Q3: 25 months)
and with metastatic BCa (n¼ 59) was 60 months (range¼ 0–300
months; Q1: 17 months; Q3: 156 months). The range of relative
Endo180 plasma levels in early BCa cases (n¼ 29) was consistent
with a normal distribution (P¼ 0.69; mean±s.d.¼ 0.92±0.37;
range¼ 0.32–1.78; Q1: 0.63; Q3: 1.13; 95% CI: 0.78–1.06,
Kolmogorov–Smirnov goodness of fit), indicating that Endo180
release into plasma during early BCa is a tightly regulated event.
Relative Endo180 levels in recurrent/metastatic BCa (n¼ 59) were
significantly elevated compared with early BCa (Po0.0001, Mann–
Whitney U-test) and inconsistent with a normal distribution
(P¼ 0.01; mean±s.d.¼ 1.71±0.87; range¼ 0.32–4.37; Q1: 1.13;
Q3: 2.30; 95% CI: 1.49–1.94, Kolmogorov–Smirnov goodness of fit)
(Figure 3A), indicating that dysregulated Endo180 release occurs at
this advanced disease stage. As expected, CA 15-3 antigen levels
were significantly higher (Po0.0001, Mann–Whitney U-test) in
recurrent/metastatic (n¼ 59) compared with early (n¼ 27) BCa
(Figure 3B).
Plasma Endo180 levels are increased in locoregional disease,
visceral metastasis and bone metastasis. To investigate whether
Endo180 was predictive of recurrent and/or metastatic disease in
visceral and/or osseous tissue, the 59 recurrent/metastatic patients
were stratified according to tissue site(s) affected by secondary
lesions. Kruskal–Wallis one-way analysis of variance with
Bonferroni correction (P¼ 0.05/n, n¼ 7) revealed that relative
Endo180 levels were significantly different (P¼ 0.0005) in early
BCa (mean±s.d.: 0.92±0.37, n¼ 29), recurrent locoregional
disease (mean±s.d.: 1.53±0.46, n¼ 5), metastases in one or more
visceral tissues (mean±s.d.: 1.78±1.20, n¼ 12), bone metastasis
alone (mean±s.d.: 1.48±0.64, n¼ 14) and bone metastasis with
additional dissemination in lung(s) (mean±s.d.: 1.72±0.61,
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P < 0.0001
104
103
102
101
Lo
g 
[C
A 
15
–3
 U
 m
l–1
]
104
103
102
101
Lo
g 
[C
A 
15
–3
 U
 m
l–1
]
P < 0.0005
P = 0.090
4
3
2
R
el
at
ive
 E
nd
o1
80
 le
ve
ls
(ar
bri
ta
ry
 u
ni
ts
)
R
el
at
ive
 
En
do
18
0 
le
ve
ls
(ar
bri
ta
ry
 u
ni
ts
)
1
0
4
3
2
1
0
Ea
rly
Ea
rly
Me
tas
tat
ic
Lo
co
reg
ion
al
Vis
ce
ral
Bo
ne
 al
on
e
Bo
ne
 + 
lun
g
Bo
ne
 + 
live
r
Bo
ne
 +

2 v
isc
era
l si
tes
Ea
rly
Ea
rly
Me
tas
tat
ic
Lo
co
reg
ion
al
Vis
ce
ral
Bo
ne
 al
on
e
Bo
ne
 + 
lun
g
Bo
ne
 + 
live
r
Bo
ne
 +

2 v
isc
era
l si
tes
Figure 3. Endo180 levels are elevated in the plasma of patients with meta-
static compared with early BCa. Plasma samples from BCa patients (n¼ 88)
were resolved on 8% w/v SDS polyacrylamide gels, transferred to polyvinyli-
dene fluoride membranes and immunoblot analysis was performed using
1mgml 1 mouse anti-human Endo180 monoclonal 39.10 antibody and
1/4000 dilution of horse radish peroxidase-conjugated goat anti-mouse IgG (a
representative blot is presented in Supplementary Figure 1). Relative plasma
Endo180 levels were calculated from the mean measurement obtained from
three analytical repeats. Plasma from the same early BCa patient was used as a
reference control (relative Endo180 level¼1.0) and the normalisation of
densitometric measurements on all analytical gels. CA 15-3 antigen concentra-
tions (Uml 1) were measured using a non-competitive two-step immunoassay
in plasma samples (n¼ 86a) collected in parallel. The box and whiskers plots
shown depict the total range, interquartile distribution, outliers (open or closed
circles) and median value (horizontal line) of relative plasma Endo180 levels
(A, C) and plasma concentrations of CA 15-3 antigen (Log10 [Uml
 1]) (B, D).
(A) The graph compares relative plasma Endo180 levels in cases of early BCa
(n¼29) and metastatic BCa (n¼ 59). (B) The graph compares plasma concen-
trations of CA 15-3 antigen (Log [Uml 1]) in cases of early BCa (n¼27a) and
metastatic BCa (n¼59). (C) The graph compares relative plasma Endo180
levels in cases of early BCa (n¼ 29) and recurrent locoregional disease (n¼5)
or metastasis in visceral tissue alone (n¼ 12), bone alone (n¼ 14) or bone with
dissemination in lung (n¼ 5), liver (n¼ 8) or two or more visceral organs
(n¼15). (D) The graph compares plasma concentrations of CA 15-3 antigen
(Log10 [Uml
 1]) in cases of early BCa (n¼27*) and metastatic sites as des-
cribed above (C). The P-values shown were determined using Mann–Whitney
U-test for comparison between cases of early BCa and metastatic BCa (A, B);
or Kruskal–Wallis one-way analysis of variance for comparison between early
BCa and recurrent/metastatic BCa stratified according to affected tissue sites
(C, D), and confirmed by Bonferroni adjustment (P¼ 0.05/n, n¼7). aData for
CA 15-3 antigenweremissing for 2 out of the 29 early BCa patients included in
the study.
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n¼ 5), liver (mean±s.d.: 2.18±0.48, n¼ 8) or X2 visceral tissue
sites (mean±s.d.: 1.71±1.09, n¼ 15) (Figure 3C). Individual
Mann–Whitney U-tests confirmed that relative Endo180 levels
increased for all metastatic sites compared with early BCa
(Po0.01). Kruskal–Wallis one-way analysis of variance conferred
a trend towards significance between CA 15-3 antigen concentra-
tions (Uml 1) in the same groups of patients (Po0.09)
(Figure 3D).
Diagnostic accuracy of Endo180. The performance of Endo180
and CA 15-3 antigen, alone and in combination, for the
classification of recurrent/metastatic vs early/localised BCa was
assessed. The respective sensitivity (% true-positive rate) and
specificity (% false-positive rate) for the classification of metastasis
by CA 15-3 antigen alone (fixed cutoff: 28Uml 1) (as used in the
Department of Medical Oncology at Imperial College NHS Trust)
was 85% and 50%. For a consecutive range of values for Endo180
alone (variable cutoff: 0.95–1.65 relative plasma levels), the
respective range of true-positive and false-positive rates for the
classification of metastasis was 82–97% and 36–54%. For CA 153
antigen (fixed cutoff: 28Uml 1) combined with Endo180
(variable cutoff: 0.95–1.65 relative levels), the respective true-
positive and false-positive rates for classification of metastasis was
94–97% and 32–48% (Supplementary Figure 2).
Modulation of Endo180 by bisphosphonates. Stratification of the
42 patients with bone metastasis (with or without additional
visceral metastasis) according to bisphosphonate treatment status
(Figure 4A) and Kruskal–Wallis one-way analysis of variance
with Bonferroni correction (P¼ 0.05/n, n¼ 3) revealed that
Endo180 levels were significantly higher in bisphosphonate-naive
cases (mean±s.d.¼ 2.17±0.79, n¼ 13) compared with those
having previous (mean±s.d.: 1.83±0.33, n¼ 5) or current
(mean±s.d.¼ 1.37±0.74, n¼ 24) bisphosphonate treatment
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Figure 4. Endo180 improves the prediction of metastatic BCa in the bisphosphonate-naive setting. (A) Stratification of all patients for which the
index test and reference standard test were performed (n¼86a) according to low or high CA 15-3 antigen and Endo180 status with respective
cutoffs of 28Uml 1 and relative plasma level of 1.15 indicated with grey arrowheads. Disease status for each patient is indicated using the
following colour code: early BCa (pink), locoregional disease (yellow), visceral metastasis alone (purple), bone metastasis alone (green) and bone
plus visceral metastasis (orange). The sensitivity (% true positives) and specificity (% false negatives) of Endo180 and CA 15-3 antigen for
classification of metastasis are indicated as fractional numbers of patients and corresponding percentages. Patients currently (*) or previously (þ )
receiving bisphosphonate treatment are indicated. Box and whiskers plots depicting the total range, interquartile distribution, outliers (open and
closed circles) and median value (horizontal line) of: (B) Endo180 and CA 15-3 antigen; in the 42 patients with bone metastasis with or without
visceral tissue metastasis classified as bisphosphonate naive (n¼13), having previously received bisphosphonates (n¼ 5) or currently being treated
with bisphosphonates (n¼ 24). The P-values shown were determined using Kruskal–Wallis one-way ANOVA, and confirmed by Bonferroni
adjustment (P¼0.05/n, n¼ 3). (C) Evaluation of the sensitivity (% true positives) and specificity (% false negatives) of Endo180 and CA 15-3 antigen
in all 57 bisphosphonate-naive patients was conducted using the same criteria as used in (A). The Endo180 cutoff (1.15) chosen for the analyses
presented in (A, C) was close to the Q1 value for recurrent/metastatic BCa (1.13) and the Q3 value for early BCa (1.13) and was higher than the
upper 95% CI for early BCa (1.06). aData for CA 15-3 antigen were missing for 2 out of the 29 early BCa patients included in the study.
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(P¼ 0.011) (Figure 4B). In contrast, CA 15-3 antigen levels were
unaltered by bisphosphonates (P¼ 0.71) (Figure 4B).
The true-positive and false-positive rates of 68% and 45% for
CA 15-3 antigen (fixed cutoff: 28Uml 1); 70–95% and 20–31%
for Endo180 alone (variable cutoff: 0.95–1.65 relative levels); and
87–92% and 21–28% for Endo180 in combination with CA 15-3
antigen in bisphosphonate-naive cases (n¼ 57) indicates that
Endo180 improves the specificity for classifying metastasis where
there is no current or prior exposure to these agents (Figure 4C).
DISCUSSION
This study provides evidence that Endo180 has the potential to
fulfil the official National Institutes of Health definition of a
biomarker as a characteristic that is objectively measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes or pharmacologic responses to a therapeutic intervention
(Diamandis, 2010). The accuracy of Endo180 for the classification
determined in this study is aligned with biomarker discoveries
made by homing-in on aberrant collagen turnover in metastatic
bone disease (Lipton et al, 2011) where Endo180 is proposed to
play a fundamental role (Caley et al, 2011; Sturge et al, 2011). In
addition, Endo180 also has a direct molecular (Behrendt et al,
2000) and functional (Sturge et al, 2003; Messaritou et al, 2009)
relationship with urokinase-type plasminogen activator, which is
currently recommended as a prognostic marker for recurrent/
metastatic BCa (Harris et al, 2007; Cardoso et al, 2011).
CA 15-3 antigen is normally present on luminal epithelial cells
lining breast ducts and its ectodomain is proteolytically cleaved by
sheddases and membrane-type I matrix metalloproteinase (MT1-
MMP) during metastasis (Thathiah et al, 2003; Thathiah and
Carson, 2004). Interestingly a co-functional relationship between
Endo180 and MT1-MMP has been reported in vivo (Wagenaar-
Miller et al, 2007) and in vitro (Messaritou et al, 2009). Together
with the observation that Endo180 and MT1-MMP are
co-expressed on epithelial and stromal cells in primary tumours
(Kogianni et al, 2009), this suggests that MT1-MMP could facilitate
Endo180 release and that the cellular source of Endo180 is tumour
and/or stromal in origin. These independent cellular mechanism(s)
and/or sources may explain the weak linear correlation between
Endo180 and CA 15-3 antigen (Supplementary Figure 3).
The elevated levels of Endo180 observed during locoregional
recurrence, visceral metastasis and bone metastasis suggests that
increased ectodomain shedding occurs when the disease becomes
active at a range of tissue sites. However, for the diagnosis of early
invasive cancer, the release of Endo180 from small asymptomatic
tumours – either from the tumour cells themselves and/or their
stromal microenvironment – will need to be detectable above
background levels in the normal population. This could be feasible
given that Endo180 participates in tumour cell and stromal cell
collagen turnover in primary tumours and osteolytic metastases
(Curino et al, 2005; Wienke et al, 2007; Caley et al, 2011),
indicating that its release could be linked to bidirectional and
heterotypic interactions between tumour and stromal cells. Since
25, out of the 29, BCa patients currently or previously receiving
bisphosphonates had metastatic lesions in their visceral tissue, as
well as bone, it is also feasible that bisphosphonates modulate
Endo180 activity at non-bone sites.
The role of bisphosphonates as an adjuvant therapy has recently
been explored in the ABCSG-12 (Austrian Breast and Colorectal
Cancer Study Group 12) and AZURE (Adjuvant Treatment with
Zoledronic Acid in Stage II/III Breast Cancer) trials. ABCSG-12
reported that addition of zoledronic to endocrine therapy reduced
disease-free survival but not overall survival in premenopausal
women with endocrine responsive BCa (Gnant et al, 2009, 2011).
In the AZURE trial, zoledronic acid did not improve disease-free
or overall survival but significantly reduced visceral metastases and
locoregional recurrence in a low oestrogen environment (Coleman
et al, 2011). Given the important role of Endo180 in collagen
remodelling – and the demonstration here that Endo180 is
suppressed by bisphosphonates – it is possible that the elevated
activity of Endo180 at locoregional and visceral sites helps drive the
bisphosphonate-sensitive mechanism identified in disseminated
tumour cells (Solomayer et al, 2012); and/or adjacent stromal cells;
in the collagen-rich microenvironments of primary and secondary
tumours.
Prospective-sample-collection and retrospective-blinded-evalua-
tion will be necessary to ascertain how Endo180 levels change as
metastatic disease develops and progresses; and to validate whether
Endo180 is an accurate diagnostic, screening or prognostic marker
in metastatic BCa. The observation that Endo180 is suppressed by
bisphosphonates suggests that it could be an indicator of response
to bisphosphonates; and should be tested in the setting of
metastatic bone disease for its prognostic accuracy in predicting
skeletal-related events in correlation with bone-targeted treatment.
In a broader context, Endo180 could also be considered as a
generalised marker for metastatic disease in other solid tumours.
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